GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Short Percentage of Float

Firebrick Pharma (ASX:FRE) Short Percentage of Float


View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Firebrick Pharma's Short Percentage of Float

For the Drug Manufacturers - General subindustry, Firebrick Pharma's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Firebrick Pharma's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Firebrick Pharma's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Firebrick Pharma's Short Percentage of Float falls into.


;
;

Firebrick Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Short Percentage of Float
Comparable Companies
ASX:ECS ASX:AGH ASX:PER ASX:CAN ASX:RGT ASX:EOF ASX:IVX ASX:EXL ASX:BP8 ASX:NXS LLY JNJ ABBV OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN MRK AMGN PFE
Traded in Other Exchanges
N/A
Address
440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000
Website
https://www.firebrickpharma.com
Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand. Its Nasodine Nasal Spray which is in the commercialization phase, is a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold. In parallel, the company is also engaged in the development of the follow-on Nasodine brand products.

Firebrick Pharma Headlines

No Headlines